Top Page
Next Science Ltd
(Sydney:NXS)
Next Science Ltd (NXS) vs. iShares MSCI Australia ETF (EWA)
Next Science Ltd Business Overview & Revenue Model
Next Science Ltd Earnings Call Summary
Next Science Ltd Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 22.82M | 22.18M | 16.90M | ― | ― | Gross Profit |
| 18.44M | 16.23M | 11.90M | ― | ― | EBIT |
| -10.30M | -15.95M | -18.31M | -9.28M | -13.96M | EBITDA |
| -9.03M | -14.42M | -17.02M | ― | -13.18M | Net Income Common Stockholders |
| -10.59M | -24.51M | -18.30M | ― | -13.27M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.67M | 9.28M | 7.54M | ― | 15.24M | Total Assets |
| 9.21M | 17.90M | 18.37M | 13.67M | 23.49M | Total Debt |
| 2.49M | 961.97K | 1.80M | ― | ― | Net Debt |
| 819.25K | -8.28M | -5.68M | ― | ― | Total Liabilities |
| 5.77M | 5.08M | 6.52M | ― | ― | Stockholders Equity |
| 3.44M | 12.82M | 11.85M | 10.73M | 18.80M |
| Cash Flow | Free Cash Flow | |||
| -8.55M | -15.94M | -17.69M | ― | -14.03M | Operating Cash Flow |
| -7.96M | -15.06M | -17.01M | ― | -13.26M | Investing Cash Flow |
| -589.22K | -884.50K | -686.23K | ― | ― | Financing Cash Flow |
| 1.75M | 20.11M | 14.78M | ― | 11.93M |
Next Science Ltd Technical Analysis
Next Science Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$43.71M | 19.12 | 4.85% | ― | 5.76% | -79.76% | |
54 Neutral | $5.34B | 3.36 | -45.10% | 3.39% | 16.81% | -0.03% | |
47 Neutral | AU$61.96M | ― | -45.40% | ― | 13.61% | -55.12% | |
45 Neutral | AU$21.39M | ― | -218.38% | ― | -14.30% | 29.69% | |
39 Underperform | $17.24M | ― | -130.18% | ― | 3.37% | 47.32% | |
| AU$33.44M | 10.00 | 4.10% | ― | ― | ― | ||
44 Neutral | AU$39.28M | ― | -19.31% | ― | 72.25% | 43.66% |
Next Science Ltd Corporate Events
Next Science Limited announced that all resolutions were passed at its 2025 Annual General Meeting, as determined by a poll. This successful meeting outcome reflects positively on the company’s governance and may reinforce stakeholder confidence, potentially impacting its market positioning favorably.
Next Science Limited held its 2025 Annual General Meeting, where the Chair and CEO highlighted significant operational improvements and strategic advancements made in 2024. The company reduced its cash burn by US$7 million, improved margins, and achieved cash flow positivity for two non-consecutive months. With a US$5 million loan facility secured, Next Science is well-positioned for future growth. Clinical research published in 2024 demonstrated the effectiveness of its products, BLASTX and XPERIENCE, in reducing infections and inflammation, contributing to lower healthcare costs. The company also continued its large-scale study on periprosthetic joint infections, enrolling 1,220 patients by the end of 2024. Despite a decline in the Durable Medical Equipment channel, Next Science achieved record revenue of US$22.8 million, driven by strong direct and partner sales.
Next Science Limited announced that a derivative complaint filed by Michael Morello in Florida’s Duval County Court has been dismissed due to lack of standing. However, the litigation initiated by Next Science LLC against Mr. Morello and other former employees for breach of post-employment restraints is still ongoing, indicating continued legal proceedings that may impact the company’s operations and stakeholder interests.
Next Science Ltd announced the cessation of 250,000 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact the company’s capital structure and could influence investor perceptions, although the specific implications for stakeholders were not detailed in the release.
Next Science Limited reported a slight decline in product sales for the first quarter of FY25, with total sales of US$5.3 million, a 3% decrease from the prior corresponding period. Despite a significant increase in direct sales of XPERIENCE and BLASTX products, the overall sales were impacted by a decline in Durable Medical Equipment (DME) sales. The company maintained a strong gross margin of 84%, attributed to a favorable product mix. Additionally, Next Science addressed an FDA Warning Letter, ensuring that their products remain safe and effective for their intended uses, and continued to focus on achieving a positive cash flow position.
Next Science Limited has released its updated corporate governance statement, which is now available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, reflecting its commitment to transparency and accountability. This move is expected to reinforce stakeholder confidence and align with industry standards, potentially impacting the company’s market perception positively.
Next Science Ltd, a company known for its innovative solutions in the medical technology industry, has released its 2024 Annual Report titled ‘A Year of Change, a Future of Growth.’ The report highlights significant developments and strategic shifts aimed at fostering growth and enhancing market positioning. The company’s focus on its XBIO® portfolio and recent studies underscores its commitment to advancing medical technology solutions. This announcement is likely to have implications for stakeholders as it signals a proactive approach towards future growth and operational enhancement.
Next Science Limited will release its first-quarter financial results for FY25 on April 24, 2025, followed by an investor webinar hosted by CEO I.V. Hall and CFO Marc Zimmerman. This announcement is part of the company’s ongoing efforts to engage with the investment community and provide transparency about its financial performance. The results and subsequent discussion could impact stakeholders’ perceptions and the company’s market positioning, particularly given its focus on innovative medical technology solutions.
Next Science Limited has announced that its 2025 Annual General Meeting (AGM) will take place on May 9, 2025, at 10:00 am Sydney time. The AGM will be a hybrid event, allowing shareholders to attend either in person at the company’s Share Registrar office in Sydney or virtually via the Zoom platform. This meeting provides an opportunity for shareholders to engage with the company, ask questions, and participate in voting, reflecting Next Science’s commitment to transparent communication and stakeholder engagement.